Replies to post #15319 on GTC Biotherapeutics (fka GTCB)

[DragonBits]

It's always a concern when a company returns a drug to the developer.

I don't recall if there were any ATRYN sales, and I don't know how profitable LEO is. Perhaps they felt they just couldn't afford to fund DIC trials. These tough economic times have changed a lot of business arrangements.